
Personalis Inc (PSNL) Stock Forecast & Price Target
Personalis Inc (PSNL) Analyst Ratings
Bulls say
Personalis Inc. has demonstrated a positive trajectory with increased volumes expected in Q4, particularly due to the anticipated marketing push by its commercial partner, Tempus. The company achieved a significant milestone by obtaining Medicare coverage and pricing for its NeXT Personal MRD test, which is poised to enhance early detection of cancer recurrence, supporting a strong value proposition in genomic testing. Additionally, the favorable agreements with large pharmaceutical partners, including a $50 million stock purchase from Merck and improved sales estimates for upcoming years, further indicate a strong growth potential for Personalis's products, reinforcing a favorable outlook for the stock.
Bears say
Personalis Inc has experienced a negative shift in its financial outlook due to a reduction in revenue guidance, attributing a significant portion of the anticipated decline to a slowdown in biopharma activities and logistical challenges with global sample processing. The company's revised revenue expectations for 2025 have been decreased to a range of $68 million to $73 million, reflecting a year-over-year decline primarily driven by reduced contributions from biopharma services. Additionally, uncertainties regarding sample flow for MRD testing and delays in reimbursement approvals further complicate the revenue landscape, signaling potential ongoing challenges in achieving profitability amidst these operational hurdles.
This aggregate rating is based on analysts' research of Personalis Inc and is not a guaranteed prediction by Public.com or investment advice.
Personalis Inc (PSNL) Analyst Forecast & Price Prediction
Start investing in Personalis Inc (PSNL)
Order type
Buy in
Order amount
Est. shares
0 shares